EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022

Lilly Josephine Bindel, Roland Seifert

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-024-03171-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Lilly Josephine Bindel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Hannover Medical School, D-30625, Hannover, Germany. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Costs, Drug Prescriptions. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, several threatening developments regarding antibacterial drugs, such as rising bacterial resistance and delivery bottlenecks, have occurred. Since antibacterial drugs are crucial for modern medicine, understanding events and influencing factors relevant for long-term developments is essential. Therefore, we analyzed the number of prescriptions and costs, defined daily dose (DDD) and DDD costs of antibacterial drugs in Germany, based on the Arzneiverordnungsreport (AVR, Drug description report) between 1985 and 2022. Based on prescription rates in 2022, we selected the TOP15 and TOP5. For a more in-depth analysis, we analyzed data from the wissenschaftliches Institut der AOK (WidO, scientific institute of the AOK). The number of prescriptions increased between 1985 and 2013, but since 2014, there has been a declining trend with a noticeable COVID-related dip. Over the years, a shift in drug classes occurred. Once very popular drugs like penicillins and tetracyclines are no longer as important. Conversely, aminopenicillins and cephalosporins have become more relevant. Particularly, the TOP5 drugs have seen an increasing proportion. DDD costs have decreased in most substance classes over time. There is a strong association between decreasing costs and rising prescriptions. Falling costs have a stronger immediate impact on prescriptions that rising costs. When costs are very low, drugs might be prescribed excessively. Supply bottlenecks can also result. The main prescribers are mainly in primary care. Their share of prescription has changed little over the years, but is decreasing regarding total consumption. In comparison to other European countries, Germany ranks in the lower third regarding prescriptions. In most countries, the COVID pandemic has led to a reduced prescription of antibacterial drugs. In conclusion, we provided a comprehensive overview of the antibacterial drug market in Germany over the past four decades and identified costs as a major driver of antibacterial drug prescriptions. Increased costs may reduce uncritical prescription of antibacterial drugs, development of bacterial resistance, supply shortages and occurrence of adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug CostsDrug PrescriptionsGermanyHumansCOVID-19Practice Patterns, Physicians'

Stichwörter der Autor:innen

Antibacterial drug consumptionAntibacterial drug prescriptionAntibacterial resistanceAntibacterial stewardshipArzneiverordnungsreportGermany

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Institute of Pharmacology, Hannover Medical School, D-30625, Hannover, Germany.
  • Institute of Pharmacology, Hannover Medical School, D-30625, Hannover, Germany. seifert.roland@mh-hannover.de.

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Bindel, L. J., & Seifert, R. (2024). Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03171-y

Vancouver

Bindel LJ, Seifert R. Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-03171-y

BibTeX
@article{Bindel2024,
  author = {Bindel, Lilly Josephine and Seifert, Roland},
  title = {Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-024-03171-y}
}
Kostenlos starten →